Influenza H3N2 Challenge - 2011 "Cure-before"
Experimental Influenza A (H3N2 A/Wisconsin/67/2005) challenge study in healthy volunteers. The purpose of this study is to investigate the early pre-symptomatic period following exposure to influenza. Participants were inoculated with HRV, and dense, longitudinal sample and data collections were performed spanning pre-inoculation baseline through infection and convalescence. This study included an early treatment group with anti-viral to compare effects of early (day one) versus late (day five) treatment on clinical symptoms and molecular signature response (2011).
- PAXgene RNA:565
- nasal lavage:845
- nasal swab:1146
Clinical: CRF/clinical data, demographics, symptom surveys, screening data
Molecular: host blood RNA microarray, virus genome seq, plasma and nasal cytokines, plasma and NP wash proteomics, virus quantitative culture, serology
- Poore et al. A miRNA Host Response Signature Accurately Discriminates Acute Respiratory Infection Etiologies. Frontiers Microbiology (2018)
- Fourati et al. A Crowdsourced Analysis to Identify Ab Initio Molecular Signatures Predictive of Susceptibility to Viral Infection. Nature Communications (2018)
- Burke et al. Nasopharyngeal Protein Biomarkers of Acute Respiratory Virus Infection. EBioMedicine (2017)
- Leonard et al. The Effective Rate of Influenza Reassortment Is Limited During Human Infection. PLoS One Pathogens (2017)
- McClain et al. A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses. Open Forum Infectious Disease (2016)
- Liu et al. An individualized predictor of health and disease using paired reference and target samples. BMC Bioinformatics (2016)